Michel Detheux

Michel Detheux

Director/Board Member at VOR BIOPHARMA INC.

Net worth: - $ as of 2026-07-30

59 year
Health Technology
Consumer Services

Profile

Michel Detheux is the founder of iTeos Therapeutics SA, founded in 2011, serving as President, Chief Executive Officer & Director.
Dr. Detheux was the founder of iTeos Therapeutics, Inc., founded in 2012, and served as President, Chief Executive Officer & Director from 2012 to 2025.
Current jobs include Chief Executive Officer at Muna Therapeutics ApS starting in 2026, Chairman at Egle Therapeutics SAS, Chairman at Innoskel SASU since 2022, and Independent Director at Vor Biopharma, Inc. since 2025.
Former jobs include President, Chief Executive Officer & Director at iTeos Belgium SA, Independent Chairman at Ona Therapeutics SL from 2021 to 2025, Executive Director at Ogeda SA, and Director at Ludwig Institute For Cancer Research Ltd. (New York) from 2010 to 2012.
Education includes a doctorate from Université Catholique de Louvain.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-06-10 0 ( -.--% ) - $ 2026-07-30

Michel Detheux active positions

CompaniesPositionStart
VOR BIOPHARMA INC. Director/Board Member 2025-07-15
Founder 2010-12-31
Chairman 2022-04-11
Chairman -
Chief Executive Officer 2026-06-28

Former positions of Michel Detheux

CompaniesPositionEnd
Chairman 2025-10-13
ITEOS THERAPEUTICS, INC. Founder 2025-08-27
Ludwig Cancer Research
Director/Board Member 2012-03-31
Chief Executive Officer -
░░░░░ ░░ ░░░░░░░░░░░░░░ ░░░░░░ -
See the detail of Michel Detheux's experience

Training of Michel Detheux

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

63

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Ludwig Cancer Research

  1. Stock Market
  2. Insiders
  3. Michel Detheux